Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Asthma
Interventions
DRUG

OC000459

OC000459 capsules 2x100mg BID for 28 days

DRUG

Placebo

Placebo capsules to match OC000459 100mg capsules, 2 tablets BID

Trial Locations (16)

105077

Research Institute of Pulmonology, Moscow

105229

Burdenko Main Military Hospital, Moscow

109240

City Hospital #23, Moscow

115446

City Hospital #7, Moscow

190068

St Petersburg Medical Academy of Postgraduate Education, Saint Petersburg

St Petersburg Medical Academy, Saint Petersburg

193231

Outpatient Clinic #94, Saint Petersburg

194017

St Petersbrug Hospital of the Russian Academy of Science, Saint Petersburg

194044

Russian Center of Emergency and Radiology Medicine, Saint Petersburg

194100

St Petersburg State Pediatrics Academy, Saint Petersburg

194291

Leningrad Regional Hospital, Saint Petersbrug

Central Medical Unit #122, Saint Petersburg

194354

Vishnevsky Central Military Hospital #3, Moscow

St George City Hospital, Saint Petersbrug

St George City Hospital, Saint Petersburg

620102

Sverdlovsk Regional Hospital #1, Yekaterinburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oxagen Ltd

INDUSTRY